-
Evaluation of peri-operative antibiotic prophylaxis in patients undergoing total joint hip or knee arthroplasty
Heidi Klotz, Lauren Kassab, Muddasser Saiyed-Javed, Sandra Hartnagle, and Sapna Shah
Publication Date: 12-6-2023
-
Evaluation of asymptomatic bacteriuria treatment
Klea Noskey, Brian Bui, Selena Hailo, Katherine Bassil, Jennifer Pilotto, and Sandra Hartnagle
Publication Date: 12-6-2023
-
Transition of continuous intravenous epoprostenol to oral treprostinil in a patient with pulmonary arterial hypertension: A patient case report
Tania Saeed, Heidi Klotz, Klea Noskey, Jacqueline Brewer, Samuel Allen, and Rebecca Baker
Publication Date: 9-28-2023
-
Impact of Continuous Infusion Ketamine as Sedation on Concomitant Opioid and Sedative Requirements in Mechanically Ventilated COVID-19 Patients
Gabrielle R. Bradley, Megan Cadiz, and Allycia Natavio
Publication Date: 12-7-2022
Characterize the impact of continuous infusion ketamine (CIK) on concomitant opioid and sedative requirements in mechanically ventilated COVID-19 patients
-
Levetiracetam for Seizure Prophylaxis in Spontaneous Intracerebral Hemorrhage
Alanah Bratley, Krystal Commons, and Allycia Natavio
Publication Date: 12-7-2022
Characterize the use of levetiracetam for early seizure prophylaxis in patients with sICH
-
Pharmacist-Provided Educational Intervention and its Impact on Medical Resident Knowledge and Comfort Level with Continuous Glucose Monitors (CGMs)
Chelsea Dezfuli, Sarah Muench, and Colleen Lauster
Publication Date: 12-7-2022
Continuous glucose monitors (CGMs) have become an integral component of diabetes care
American Diabetes Association now recommends that CGMs be offered to all patients on insulin who can use the device safely
Integrating CGMs into clinical practice can be challenging for several reasons: – Data overload – Cost – Need for education on data interpretation
-
Evaluation of Antimicrobial Prophylaxis in Spine Surgery within an Enhanced Recovery Program at a Large Community Teaching Hospital
Sabrina DiPietro, Klea Noskey, Richard Zoltowski, Tania Saeed, and Sapna Shah
Publication Date: 12-7-2022
The risk of surgical site infections post spine surgery is 0% to 18%.1
• American Society of Health System Pharmacists (ASHP) and Enhanced Recovery After Surgery (ERAS) Society guidelines recommend using an agent with activity against the most common surgical site pathogens including Staphylococcus aureus. 2,3
• The preferred agent is cefazolin 2 grams intravenous (IV) (3 grams if patient weighs ≥120 kilograms [kg]) administered 30 minutes prior to skin incision and re-dosed every four hours intraoperatively.2,3
• In the case of a cephalosporin allergy, clindamycin 900 milligrams (mg) IV or vancomycin 15 mg/kg IV are recommended alternatives.2,3
• Due to lack of appropriate documentation of allergies in the electronic medical record (EMR), alternative antimicrobials are often prescribed.
-
Impact of Soy-Based Versus Composite Lipid Emulsion (Soybean, Medium Chain Triglycerides, Olive and Fish Oil) in Critically Ill Patients
Sandra Kless, Lisa Hall Zimmerman, and Olaf Kroneman
Publication Date: 3-2022
-
Evaluation of Antibiotic Selection and Duration in Patients with Non-Severe Community Acquired Pneumonia
Emily Reich, Sandra Hartnagle, Jennifer Pilotto, Heidi Klotz, and Ryan Herc
Publication Date: 12-7-2022
-
Evaluation of Safety Outcomes of Two Hydrocortisone Dosing Regimens in Patients in Septic Shock
Alexandra Rola, Joshua Wirtz, Daniel Kalaj, Vasil Rrushi, and Megan Cadiz
Publication Date: 12-7-2022
• Steroids are used in shock to minimize the impact of shock-induced dysregulation of inflammatory response – Hydrocortisone is preferred for its activity as a glucocorticoid and a mineralocorticoid • Available data on the use of hydrocortisone shows mixed benefit – Data to guide dosing is limited, use of 100 mg IV every 8 hours may have benefit over 50 mg IV every 6 hours • Use of steroids has been associated with potential risks, including gastrointestinal bleeding, hyperglycemia, hypernatremia, superinfection, etc.
-
Ertapenem Versus Meropenem for the Treatment of ESBL-Producing Enterobacterales Bacteremia in Critically Ill Patients
Sydney VanDorf, Prakash Shah, Chad Richardson, and Christine Yost
Publication Date: 12-7-2022
The purpose of this study is to evaluate clinical outcomes for critically ill patients receiving ertapenem or meropenem for ESBL-producing Enterobacterales bacteremia.
-
Safety Evaluation of Intravenous Heparin Protocol Following Alteplase Treatment in Patients with Suspected or Confirmed Pulmonary Embolism
Erika Waldsmith, Lisa Hall Zimmerman, and Claudia Hanni
Publication Date: 12-7-2022
Printing is not supported at the primary Gallery Thumbnail page. Please first navigate to a specific Image before printing.